Sunvozertinib

Brand names: Zegfrovy · Active ingredient: Sunvozertinib

In short: ZEGFROVY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test , whose disease has progressed on or after platinum-based che

Forms & strengthsTablets: 150 mg: yellow, biconvex film-coated tablets, debossed with "150" on one side and Dizal company logo on the other side. 200 mg: yellow, biconvex film-coated tablets, debossed with "200" on one side and Dizal company logo on the other side.
LabelDizal Pharmaceutical Co., Ltd.
Label updatedOct 23, 2026

What is Sunvozertinib used for?

ZEGFROVY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test , whose disease has progressed on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Sunvozertinib dosage

Select patients for treatment with ZEGFROVY for locally advanced or metastatic NSCLC based on the presence of EGFR exon 20 insertion mutations in tumor tissue . Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics.

The recommended dosage of ZEGFROVY is 200 mg orally once daily with food until disease progression or unacceptable toxicity. Swallow ZEGFROVY tablets whole. Do not split, crush, chew, or dissolve the tablets. Take ZEGFROVY at the same time each day.

Missed Dose

If a dose of ZEGFROVY is missed within 12 hours, take the dose. If a dose of ZEGFROVY is missed by more than 12 hours, skip the missed dose and take the next dose at the regularly scheduled time.

Vomiting

If a ZEGFROVY dose is vomited, do not take an additional dose. Take the next dose at the regularly scheduled time.

Reduce the dose of ZEGFROVY to 150 mg orally once daily with food, for the management of adverse reactions. Permanently discontinue ZEGFROVY in patients unable to tolerate 150 mg orally once daily.

The recommended dosage modifications for adverse reactions are provided in Table 1.

Adverse Reaction | SeverityAdverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). | Dose Modifications

Interstitial Lung Disease (ILD)/Pneumonitis | Any Grade | Withhold ZEGFROVY if ILD/pneumonitis is suspected.

Permanently discontinue ZEGFROVY if ILD/pneumonitis is confirmed.

Nausea or Vomiting | Grade 1 | Administer supportive care including anti-emetics.

Grade 2 | Administer supportive care including anti-emetics.

Withhold ZEGFROVY until recovery to Grade ≤1; then resume ZEGFROVY at the same dose.

Grade 3 or 4 | Administer supportive care including anti-emetics.

Withhold ZEGFROVY until recovery to Grade ≤1; then resume ZEGFROVY at the next lower dose.

Diarrhea | Grade 1 | Administer supportive care including anti-diarrheals (i.e., loperamide).

Grade 2 or 3 | First occurrence

Administer supportive care and anti-diarrheals (i.e., loperamide).

Withhold ZEGFROVY until recovery to Grade ≤1; then resume ZEGFROVY at the same dose level.

Recurrence

Withhold ZEGFROVY until recovery to Grade ≤1; then resume ZEGFROVY at the next lower dose.

Grade 4 | First occurrence

Withhold ZEGFROVY and provide supportive care and anti-diarrheals (i.e., loperamide).

If resolved to Grade ≤1 within 3 weeks, resume ZEGFROVY at the next lower dose.

If not resolved to Grade ≤1 within 3 weeks, permanently discontinue ZEGFROVY.

Recurrence

Permanently discontinue ZEGFROVY.

Dermatologic Adverse Reactions | Grade 2 | Administer supportive care.

Reassess within 3 weeks, if rash does not improve, consider ZEGFROVY dose reduction.

Grade 3 | Withhold ZEGFROVY and administer supportive care. …

How to take Sunvozertinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Interstitial Lung Disease/Pneumonitis

Advise patients that ZEGFROVY can cause interstitial lung disease/pneumonitis. Advise patients to immediately contact their healthcare provider for new or worsening respiratory symptoms .

Gastrointestinal Toxicity

Advise patients that ZEGFROVY can cause gastrointestinal toxicity, including nausea, vomiting, and diarrhea. Advise patients to take ZEGFROVY with food to reduce gastrointestinal adverse reactions. Advise patients to immediately contact their healthcare provider for symptoms of gastrointestinal toxicity .

Dermatologic Adverse Reactions

Advise patients that ZEGFROVY can cause dermatologic adverse reactions, including rash and pruritus. Advise patients to use alcohol-free (e.g., isopropanol-free, ethanol-free) emollient cream during treatment with ZEGFROVY and to avoid the use of irritating skin products (e.g., products containing retinol or retinoic acid, benzoyl peroxides). Advise patients to immediately contact their healthcare provider for symptoms of dermatologic adverse reactions . …

Warnings & precautions

Do not take this medicine if: None.

ZEGFROVY can cause severe and life-threatening interstitial lung disease (ILD)/pneumonitis.

In the safety population , ILD/pneumonitis occurred in 1.7% of patients. The median time to first onset for ILD/pneumonitis was 61 days (range: 35 to 86 days). ZEGFROVY was discontinued due to ILD/pneumonitis in 0.8% of patients.

Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, and fever). Immediately withhold ZEGFROVY in patients with suspected ILD/pneumonitis and permanently discontinue ZEGFROVY if ILD/pneumonitis is confirmed .

ZEGFROVY can cause severe gastrointestinal adverse reactions including diarrhea, nausea, and vomiting.

In the safety population , serious gastrointestinal adverse reactions occurred in 1.7% of patients, including 0.8% Grade 3 nausea. Diarrhea occurred in 73% of patients who received ZEGFROVY, including 2.5% Grade 3. Diarrhea leading to dosage interruption or dose reduction occurred in 5% of patients and required permanent discontinuation of ZEGFROVY in 0.8% of patients. Nausea and vomiting occurred in 43% of patients, including 3.3% Grade 3 events. Nausea and vomiting leading to dosage interruption or dose reduction occurred in 7% of patients and permanent discontinuation of ZEGFROVY in 0.8% of patients.

Administer ZEGFROVY with food to reduce gastrointestinal adverse reactions. Monitor patients for gastrointestinal toxicity, and provide supportive care, including anti-diarrheals, anti-emetics, or fluid replacement, as indicated. Withhold, reduce the dose, or permanently discontinue ZEGFROVY based on severity .

ZEGFROVY can cause severe rash including acneiform dermatitis and pruritus.

Based on the safety population , dermatologic adverse reactions occurred in 68% of patients including 9% acneiform dermatitis. …

Sunvozertinib side effects

The following adverse reactions are described elsewhere in the labeling:

Interstitial Lung Disease/Pneumonitis

Gastrointestinal Adverse Reactions

Dermatologic Adverse Reactions

Ocular Toxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety populations described in WARNINGS AND PRECAUTIONS reflect exposure to ZEGFROVY as a single agent at a dose of 200 mg orally once daily in 121 patients with locally advanced or metastatic NSCLC from two clinical trials WU-KONG1 (NCT03974022) and WU-KONG2 (n=3). Among 121 patients who received ZEGFROVY, 56% were exposed for 6 months or longer and 28% were exposed for greater than one year. In this pooled safety population, the most common (≥20%) adverse reactions were diarrhea, rash, decreased appetite, stomatitis, fatigue, nausea, paronychia, vomiting, constipation, musculoskeletal pain, pruritus, dry skin, urinary tract infection, abdominal pain and decreased weight. …

Drug interactions

Table 4 describes drug interactions where coadministration with another drug affects ZEGFROVY.

Strong CYP3A Inhibitors

Prevention or Management | Avoid concomitant use with strong CYP3A inhibitors.

If concomitant use cannot be avoided, reduce ZEGFROVY dose as recommended and monitor for increased ZEGFROVY adverse reactions.

Mechanism and Clinical Effect(s) | Sunvozertinib is a CYP3A substrate.

Concomitant use with strong CYP3A inhibitors increases sunvozertinib exposure , which may increase the risk of ZEGFROVY-associated adverse reactions.

Strong or Moderate CYP3A Inducers

Prevention or Management | Avoid concomitant use with strong and moderate CYP3A inducers.

If concomitant use cannot be avoided, increase ZEGFROVY dose as recommended .

Mechanism and Clinical Effect(s) | Sunvozertinib is a CYP3A substrate.

Concomitant use with strong or moderate CYP3A inducers decreases sunvozertinib exposure , which may reduce effectiveness of ZEGFROVY.

Table 5 describes drug interactions where coadministration with ZEGFROVY affects another drug.

Hormonal Contraceptives (CYP3A Substrates)

Prevention or Management | Avoid concomitant use of ZEGFROVY with hormonal contraceptives. …

About this medicine

ZEGFROVY (sunvozertinib) is a kinase inhibitor. The molecular formula for sunvozertinib is C29H35ClFN7O3, and the molecular weight is 584.09 g/mol. The chemical name of sunvozertinib is N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide. Sunvozertinib has one chiral carbon with R-configuration. The chemical structure of sunvozertinib is shown below:

ZEGFROVY tablets contain 150 mg or 200 mg of active ingredient sunvozertinib. Inactive ingredients in ZEGFROVY core tablets are colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablet coating consists of hypromellose 2910, iron oxide yellow, titanium dioxide, and triacetin.

How it works: Sunvozertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds to and inhibits EGFR exon 20 insertion mutations at similar concentrations as wild-type EGFR. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 349fa84e-1fdb-4976-b1bb-689b80eac8ad. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate